This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prot, M.
Right arrow Articles by Binétruy, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prot, M.
Right arrow Articles by Binétruy, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 3998-4004, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00625-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice{triangledown}

Matthieu Prot,1,2 Laurence Heripret,1,2,3 Nathalie Cardot-Leccia,4 Christophe Perrin,4 Myriam Aouadi,1,2 Thibaud Lavrut,5 Rodolphe Garraffo,5 Pierre Dellamonica,3 Jacques Durant,3 Yannick Le Marchand-Brustel,1,2 and Bernard Binétruy1,2,6,7*

INSERM, U568, Nice, F-06107, France,1 Université de Nice Sophia-Antipolis, Faculté de Médecine, av de Valombrose, Nice, F-06107, France,2 CHU de Nice, Service d'Infectiologie Hôpital l'Archet-1, route de saint Antoine de Ginestière, 06202 Nice, France,3 CHU de Nice, Laboratoire Central d'Anatomie Pathologique, Hôpital Pasteur, 20 av de la voie romaine, BP 69, 06002 Nice, France,4 CHU de Nice, Laboratoire de Pharmacologie-Toxicologie, Hôpital Pasteur, 20 av de la voie romaine, BP 69, 06002 Nice, France,5 INSERM, U626, Marseille, F-13385, France,6 Université de la Méditerranée, Faculté de Médecine La Timone, 26 bd J Moulin, 13385 Marseille, France7

Received 22 May 2006/ Returned for modification 6 July 2006/ Accepted 14 September 2006

Highly active antiretroviral therapy (HAART) of human immunodeficiency virus-infected patients is associated with adverse effects, such as lipodystrophy and hyperlipidemia. The lipodystrophic syndrome is characterized by a peripheral lipoatrophy and/or fat accumulation in the abdomen and neck. In order to get insights into the physiopathological mechanisms underlying this syndrome, we treated mice with protease inhibitors (PIs) over a long period of time. Although atazanavir-treated mice presented the same circulating triglyceride concentration as control mice, lopinavir-ritonavir-treated mice rapidly became hypertriglyceridemic, with triglyceride levels of 200 mg/dl, whereas control and atazanavir-treated animals had triglyceride levels of 80 mg/dl. These results obtained with mice reproduce the metabolic disorder observed in humans. White adipose tissue (WAT) was analyzed after 8 weeks of treatment. Compared to the control or atazanavir treatment, lopinavir-ritonavir treatment induced a significant 25% weight reduction in the peripheral inguinal WAT depot. By contrast, the profound epididymal WAT depot was not affected. This effect was associated with a 5.5-fold increase in SREBP-1c gene expression only in the inguinal depot. Our results demonstrate that the long-term treatment of mice with PIs constitutes an interesting experimental model with which some aspects of the lipoatrophy induced by HAART in humans may be studied.

* Corresponding author. Mailing address: INSERM U626, Faculté de Médecine La Timone, 26 bd J Moulin, 13385 Marseille, France. Phone: (33) 4 9132 4406. Fax: (33) 4 9125 4336. E-mail: Bernard.Binetruy{at}medecine.univ-mrs.fr.

{triangledown} Published ahead of print on 25 September 2006.

Antimicrobial Agents and Chemotherapy, December 2006, p. 3998-4004, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00625-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Flint, O. P., Noor, M. A., Hruz, P. W., Hylemon, P. B., Yarasheski, K., Kotler, D. P., Parker, R. A., Bellamine, A. (2009). The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications. Toxicol Pathol 37: 65-77 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»